The Smokeout Turned 50. The Science Says the Cigarette Filter Was Always a Sales Pitch.
Three new studies in Addiction this week explain why quitting nicotine is harder than it looks: the filter that reassures you, the vape that reminds you, and the pouch that finds the people already hooked.
In 1965, 42% of American adults smoked. By 2024 it was about 10%, and the American Cancer Society marked the 50th Great American Smokeout on November 19 by warning that the progress is “at risk”, with its CEO Shane Jacobson saying “the tobacco industry is recycling the same old playbook.” If you are one of the 10% — or you quit and still dream about it — three studies published in the journal Addiction this week explain why the last stretch is the hardest.
The cigarette filter was never a safety device. It is a permission slip — and the science now shows it.
Start with the filter. In a randomized experiment of 3,961 adults in Great Britain, researchers showed people either filtered or filterless cigarettes and asked which they’d pick to smoke. Among current smokers, 94.2% chose a cigarette when it had a filter; only 67.4% did when it didn’t. That is a huge gap for a strip of plastic fibers that doesn’t make smoking safer. The filter works on your mind, not your lungs: it makes the thing feel cleaner, milder, more acceptable. The authors argue that regulating or banning filters could serve both public health and the environment. Your instinct that the filter “helps” is exactly what it was designed to produce.
Then the craving. A study of 70 young adults who both smoke and vape found that seeing e-cigarette cues — the device, someone using one — raised their desire for an actual cigarette. In plain terms: the brain learns to treat anything associated with nicotine as a signal that nicotine is coming, and it starts asking for it. That is why switching to a vape can keep the cigarette door propped open, and why people who quit often relapse in the exact places they used to smoke.
And the newcomer. Using national survey data on nearly 24,000 adults who had never tried nicotine pouches, Yang and Lin found that only 0.8% started over the study period — but those who did were overwhelmingly people already using tobacco, and adults 18 to 24 were more than eight times as likely to start as those 45 and older. Pouches mostly aren’t converting non-users; they are giving people already dependent on nicotine another way to stay that way. (We covered the teen side of pouches last week.)
For anyone counseling patients this week: when someone says they “switched” to a vape or pouch, ask whether they still smoke at all — dual use is the common outcome — and plan for cue triggers by place and time, not just by product.
If you’re trying to quit, your cravings aren’t weakness. They are a learned signal, built on purpose, and learned signals can be unlearned. Since 1965, roughly a third of the adult population has unlearned it. You are allowed to be next.
More in our nicotine and tobacco hub.
Sources Cited
- 01.B
- 02.A
- 03.A
- 04.A
Filed Under
sciencebiologypsychologyNicotineVapingPeer-Reviewed ResearchYouth & Young AdultsRelapse Prevention
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Benzodiazepines Hurt People Twice: When They're Handed Out Carelessly, and When They're Taken Away the Same Way
Benzodiazepine prescriptions fell 26.7% over a decade, the 2025 tapering guideline says dependence is not addiction, and bromazolam is spreading through the fentanyl supply. What people taking or using benzos need to know now.
Science & MedicineThe VA Is Testing Ozempic's Ingredient on Drinking. The Last Trial Says Watch the Heavy Days, Not the Craving.
The VA launched a randomized trial of semaglutide (the drug in Ozempic and Wegovy) for veterans with alcohol use disorder. What two earlier trials found, what's still unproven, and the alcohol medications that already work.
Science & MedicineNine Drugs, 2,000 Patients, No Pill for Cocaine or Meth. Maybe We've Been Grading the Trials Wrong.
There is still no FDA-approved medication for cocaine or methamphetamine addiction. A 2026 JAMA Psychiatry meta-analysis argues abstinence-only trial endpoints hide real progress, and contingency management remains the strongest tool. What it means if you're trying to cut back.